Analysts Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $78.80

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been given a consensus recommendation of “Moderate Buy” by the five brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $78.80.

A number of research analysts have weighed in on ANIP shares. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Truist Financial reiterated a “hold” rating and issued a $60.00 price objective (down previously from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Finally, Raymond James upped their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $63.44, for a total value of $1,268,800.00. Following the completion of the transaction, the senior vice president now directly owns 193,226 shares of the company’s stock, valued at $12,258,257.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 14,257 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total transaction of $900,472.12. Following the completion of the transaction, the chief operating officer now owns 635,363 shares of the company’s stock, valued at approximately $40,129,527.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $63.44, for a total value of $1,268,800.00. Following the sale, the senior vice president now owns 193,226 shares in the company, valued at $12,258,257.44. The disclosure for this sale can be found here. Insiders have sold 46,007 shares of company stock valued at $2,911,790 in the last 90 days. 12.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of ANIP. Allspring Global Investments Holdings LLC boosted its holdings in ANI Pharmaceuticals by 287.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock valued at $1,471,000 after purchasing an additional 15,790 shares during the period. Great Lakes Advisors LLC boosted its stake in ANI Pharmaceuticals by 67.1% during the fourth quarter. Great Lakes Advisors LLC now owns 48,252 shares of the specialty pharmaceutical company’s stock valued at $2,661,000 after buying an additional 19,378 shares during the period. BNP Paribas Financial Markets grew its position in ANI Pharmaceuticals by 106.9% during the first quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock worth $1,434,000 after buying an additional 10,716 shares in the last quarter. Wakefield Asset Management LLLP bought a new position in ANI Pharmaceuticals in the 1st quarter worth about $979,000. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $600,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $58.52 on Wednesday. The stock has a 50 day moving average of $60.89 and a 200 day moving average of $63.58. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of 36.58 and a beta of 0.71. ANI Pharmaceuticals has a 12 month low of $48.20 and a 12 month high of $70.81. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. The company had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business’s revenue for the quarter was up 18.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.06 EPS. As a group, sell-side analysts forecast that ANI Pharmaceuticals will post 3.5 earnings per share for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.